Sep 10, 2008 - VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that it has received a determination from the U.S. Food and Drug Administration (FDA) that Xyfid(TM) (1% uracil topical) is a drug rather than a device and would be regulated with the Center for Drug Evaluation and Research (CDER) as opposed to the Center for Devices and Radiologic Health (CDRH).
The details can be read here.
No comments:
Post a Comment